2-methoxyestradiol has been researched along with navitoclax in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Cho, SY; Jang, D; Jeong, EM; Jung, HR; Kang, J; Kim, J; Lee, C; Lee, SE; Lee, WS; Min, S; Oh, Y; Shin, S; Sung, CO | 1 |
2 other study(ies) available for 2-methoxyestradiol and navitoclax
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Topics: 2-Methoxyestradiol; Aniline Compounds; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Proto-Oncogene Proteins p21(ras); Sulfonamides; Superoxide Dismutase; Thioredoxins; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |